Study of Isatuximab, Lenalidomide, and Dexamethasone for Patients with High-Risk Smoldering Multiple Myeloma

3 1 1 1

What is this study about?

This clinical trial is focused on studying a condition known as high-risk smoldering multiple myeloma, which is a type of blood cancer that affects plasma cells in the bone marrow. The study is investigating the effectiveness of a treatment combination that includes isatuximab (also known by its code name SAR650984), lenalidomide, and dexamethasone. These medications are being tested to see if they can help delay the progression of the disease compared to using lenalidomide and dexamethasone alone.

The purpose of the study is to determine if adding isatuximab to the treatment can provide additional benefits for patients with high-risk smoldering multiple myeloma. Participants in the study will receive either the combination of isatuximab, lenalidomide, and dexamethasone or just lenalidomide and dexamethasone. The study will monitor the safety and effectiveness of these treatments over time.

Throughout the study, participants will be closely observed to assess how well the treatment works and to identify any side effects. The study aims to provide valuable information on whether the addition of isatuximab can improve outcomes for patients with this condition. The trial is expected to continue for several years to gather comprehensive data on the long-term effects of the treatment.

1 joining the study

Upon joining the study, the participant will be informed about the trial’s objectives and procedures. The participant must provide written consent to participate.

2 safety run-in phase

The initial phase involves confirming the recommended dose of isatuximab when combined with lenalidomide and dexamethasone.

Participants will receive isatuximab through intravenous infusion. The dosage and frequency will be determined based on safety assessments.

3 randomized phase 3

Participants will be randomly assigned to receive either the combination of isatuximab, lenalidomide, and dexamethasone or lenalidomide and dexamethasone alone.

The goal is to evaluate the clinical benefit of adding isatuximab in terms of prolonging the time before the disease progresses.

4 medication administration

Isatuximab is administered intravenously. The specific schedule will be provided by the study team.

Lenalidomide is taken orally in capsule form. The dosage may vary, including options like 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg capsules.

Dexamethasone is available in tablet form and is also taken orally. The dosage will be specified by the study team.

5 monitoring and assessments

Regular monitoring will occur to assess safety and effectiveness. This includes checking for any adverse effects and measuring the concentration of isatuximab in the blood.

Participants will undergo various assessments to evaluate their response to the treatment and any changes in their condition.

6 end of participation

The study is estimated to conclude by May 30, 2034. Participants will be informed about the end of their involvement and any follow-up procedures.

Who Can Join the Study?

The participant must be at least 18 years old or older.
The participant should have been diagnosed with high-risk smoldering multiple myeloma (SMM) within the last 5 years. This is a condition where there are certain proteins in the blood or urine, or specific cells in the bone marrow, but without symptoms of myeloma.
The participant should have an ECOG Performance Status of 0, 1, or 2. This is a scale that measures how well a person can perform daily activities.
The participant must be able to provide written consent voluntarily.
The participant’s absolute neutrophil count (ANC) should be at least 1000/µL. This is a measure of a type of white blood cell important for fighting infections.
The participant should have at least 50,000 platelets/µL. Platelets are cells that help with blood clotting.
The participant’s total bilirubin should be 3 mg/dL or less, unless they have Gilbert syndrome, in which case the direct bilirubin should be 5 mg/dL or less. Bilirubin is a substance made by the liver.
The participant’s alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels should be no more than 3 times the upper limit of normal. These are enzymes that help assess liver function.

Who Cannot Join the Study?

Patients who have a different type of cancer other than high-risk smoldering multiple myeloma cannot participate.
Patients who are not within the specified age range for the study cannot participate.
Patients who are not able to follow the study procedures or take the study medications as required cannot participate.
Patients who have certain medical conditions that might interfere with the study cannot participate.
Patients who are pregnant or breastfeeding cannot participate.
Patients who have had another cancer within the last five years, except for certain skin cancers or in situ cancers, cannot participate.
Patients who have received certain treatments for their condition recently cannot participate.
Patients who have an active infection that requires treatment cannot participate.
Patients who have a history of severe allergic reactions to similar medications cannot participate.
Patients who have certain heart conditions that are not well controlled cannot participate.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country
IRCCS Humanitas Research Hospital	Rozzano	Italy
Hospital Universitario De Salamanca	Salamanca	Spain
Centre Hospitalier Universitaire De Lille	Lille	France
Oslo Universitetssykehus HF	Oslo	Norway
Hospital Universitario De Navarra	Pamplona	Spain
CHU Grenoble Alpes	La Tronche	France

Other Sites

Site Name	City	Country
University Hospital Ostrava	Ostrava	Czechia
Fakultni Nemocnice Hradec Kralove	Novy Hradec Kralove	Czechia
Semmelweis University	Budapest	Hungary
Del-Pesti Centrumkorhaz Orszagos Hematologiai Es Infektologiai Intezet	Budapest	Hungary
Hopital Beaujon	Clichy	France
Centre Hospital Region Metz Thionville	Metz	France
University Hospital Olomouc	Olomouc	Czechia
Cdhxyz Htrdqwdbnrj Dtyiuwcajsugx Vujqzy	La Roche sur Yon	France
Ejpfvciimpfa Swtx	Athens	Greece
Rzxvux Sljderqiq	Holbæk	Denmark
Igztcgxt Rvittuuqd Pdw Lh Sjcjvh Dlb Toptvu Dllk Ajkknia Izef Srazuu	Meldola	Italy
Ahqaljywe Hyxxizyb	Athens	Greece
Hrnouyhi Cphdll Dc Bgkwevjlt	Barcelona	Spain
Hmfss Bcaeeo Hp	Bergen	Norway
Vfmbtliw uvtqjurzmzpq lpuxejqt Seqegrdp kcsfgljh Vvt	Vilnius	Lithuania
Fmthzdng Numrdngin Bayp	Brno	Czechia
Umsiokrddcelduvus Pzlqglwvwip Dkcef Mokczo	Ancona	Italy
Agklehd Uufnaflbpj Hjkuwcuz	Aalborg	Denmark
Chaojl Hiiymgaquqc Dx Lu Cthu Bjkylg	Bayonne	France
Uupecmzavdmrvclvtrkqe Hanatkhduz Abt	Heidelberg	Germany
Vzdvebfos Fniidhzo Nwevmsggc V Pgfai	Prague	Czechia
Cgiexj Hxaonmuyjyc Unmviqpogswwr Dw Rhatko	Rennes	France
Rdbuxeawjzxsbk	Copenhagen	Denmark
Urfsvfakumstyq Csbqlpa Kaawetarl	Gdansk	Poland
Hieypolg Dn Ly Ssvvi Ccnj I Saeg Pos	Barcelona	Spain
Ubmeydquja Mfhrcse Crpltr Hcfgtpgupzokjnilt	Hamburg	Germany
Hkpaefst Ukcnhtfdmrktl 1c Do Oitvkvh	Madrid	Spain
Whocvkvwvky Wckpmstdgjlnzcjpkyqt Cvnzvwg Oigpviwjm I Taobcovxdbgem Io Miyqwfyxirq W Lpujt	Lodz	Poland
Hnqgticf Cleosvc Ufuxggsoyudvu Lrqxsb Byort	Zaragoza	Spain
Hqqsika Skjox Aczwfqf	Paris	France
Sbmcqf Vwlsqtuun Kpivka Mzi Odhbbc Kmbcvz	Kaposvar	Hungary
Tiqoxeolor Czxphl Hitrwkyh	Thessaloniki	Greece
Ckrxqm Hlxvzqbwloj Ufpluxydhhlpp Dn Plddfssv	Poitiers	France
Ajptwwb Oiiitlysefo S Mcsgk Dd Tpryy	Terni	Italy
Hhfsllgj Uygkewzlyroxr Dx Padrn Akmpmadkoq	Valencia	Spain

Trial status

Country	Status	Recruitment Start
Czechia	Not recruiting	16.06.2020
Denmark	Not recruiting	16.06.2020
France	Not recruiting	16.06.2020
Germany	Not recruiting	16.06.2020
Greece	Not recruiting	16.06.2020
Hungary	Not recruiting	16.06.2020
Italy	Not recruiting	16.06.2020
Lithuania	Not recruiting	16.06.2020
Norway	Not recruiting	16.06.2020
Poland	Not recruiting	16.06.2020
Spain	Not recruiting	16.06.2020

Trial locations

Investigated Drugs:

Isatuximab is a medication being studied for its potential to help treat high-risk smoldering multiple myeloma. It is used in combination with other medications to see if it can help delay the progression of the disease. Isatuximab works by targeting specific proteins on the surface of cancer cells, which may help the immune system to attack and destroy these cells.

Lenalidomide is a medication that is part of the treatment being tested in this study. It is used to help slow down or stop the growth of cancer cells. Lenalidomide can also help the immune system work better to fight cancer.

Dexamethasone is a type of steroid medication included in the treatment plan. It is used to reduce inflammation and help manage symptoms associated with multiple myeloma. Dexamethasone can also enhance the effects of other cancer treatments.

Investigated Diseases:

Plasma cell myeloma

Plasma Cell Myeloma – Plasma cell myeloma, also known as multiple myeloma, is a type of blood cancer that originates in the plasma cells, which are a type of white blood cell responsible for producing antibodies. In this disease, abnormal plasma cells multiply uncontrollably in the bone marrow, leading to the production of a large amount of abnormal proteins. This can result in damage to bones, kidneys, and the immune system. Patients may experience symptoms such as bone pain, fatigue, frequent infections, and anemia. Over time, the disease can cause significant bone damage and other complications. The progression of plasma cell myeloma can vary, with periods of stability followed by active disease phases.

Trial ID:

2023-507419-37-00

Protocol code:

EFC15992

Trial Phase:

Therapeutic confirmatory (Phase III)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study of Isatuximab, Lenalidomide, and Dexamethasone for Patients with High-Risk Smoldering Multiple Myeloma

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?